合計 50 件の最近のインサイダー取引記録が記録されています Calithera Biosciences, Inc. (CALA), 内訳は 25 件の買い および 25 件の売り. インサイダー買い総額は $1.11M インサイダー売り総額は $80.46M.
最近活動のある主要インサイダーには Takeda Pharmaceutical Co Ltd, Pakianathan Deepika, Molineaux Susan. インサイダー取引記録は、経営陣が株式の評価と将来の見通しをどう見ているかについての洞察を提供します.
インサイダー取引記録 — CALA
| 日付 |
氏名 |
役職 |
取引種別 |
株数 |
平均価格 |
価値 |
保有株数 |
| 2023-04-17 |
Takeda Pharmaceutical Co Ltd |
Officer |
その他(売り) |
1,000,000 |
$40.08 |
$40.08M |
- |
| 2023-01-27 |
Pakianathan Deepika |
Director |
情報に基づく売り |
1,172 |
$0.39 |
$452.16 |
- |
| 2023-01-23 |
Molineaux Susan |
President & CEO |
RSU 源泉徴収 |
526 |
$0.45 |
$234.65 |
27,859 |
| 2023-01-23 |
Wong Stephanie |
See Remarks |
RSU 源泉徴収 |
317 |
$0.45 |
$141.41 |
6,287 |
| 2023-01-23 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU 源泉徴収 |
279 |
$0.45 |
$124.46 |
8,467 |
| 2023-01-23 |
Molineaux Christopher |
Sr. VP, Development |
RSU 源泉徴収 |
217 |
$0.45 |
$96.80 |
27,859 |
| 2023-01-23 |
Kuriakose Emil |
Chief Medical Officer |
RSU 源泉徴収 |
79 |
$0.45 |
$35.24 |
3,539 |
| 2022-07-01 |
Takeda Pharmaceutical Co Ltd |
10 Percent Owner |
その他(売り) |
1,000,000 |
$40.08 |
$40.08M |
- |
| 2022-07-01 |
Takeda Ventures, Inc. |
Director |
その他(売り) |
1,000,000 |
- |
- |
- |
| 2022-06-01 |
Pakianathan Deepika |
Director |
RSU 付与(制限付株式) |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Wolff Henry Ward |
Director |
RSU 付与(制限付株式) |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Garland J. Scott |
Director |
RSU 付与(制限付株式) |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Agarwal Sunil |
Director |
RSU 付与(制限付株式) |
20,000 |
- |
- |
20,000 |
| 2022-06-01 |
Wise Blake |
Director |
RSU 付与(制限付株式) |
20,000 |
$0.20 |
$4K |
20,000 |
| 2022-06-01 |
Orford Keith |
Director |
RSU 付与(制限付株式) |
20,000 |
$0.20 |
$4K |
20,000 |
| 2022-06-01 |
Jones Suzy |
Director |
RSU 付与(制限付株式) |
20,000 |
- |
- |
20,000 |
| 2022-01-25 |
Molineaux Susan |
President & CEO |
RSU 付与(制限付株式) |
597,475 |
$0.44 |
$262.89K |
597,475 |
| 2022-01-25 |
Wong Stephanie |
See Remarks |
RSU 付与(制限付株式) |
215,000 |
$0.44 |
$94.6K |
215,000 |
| 2022-01-25 |
Ray Sumita |
See Remarks |
RSU 付与(制限付株式) |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU 付与(制限付株式) |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Molineaux Christopher |
Sr. VP, Development |
RSU 付与(制限付株式) |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Orford Keith |
Director |
RSU 付与(制限付株式) |
40,000 |
$0.44 |
$17.6K |
40,000 |
| 2022-01-25 |
Parlati Francesco |
Sr. VP, Research |
RSU 付与(制限付株式) |
165,000 |
$0.44 |
$72.6K |
165,000 |
| 2022-01-25 |
Kuriakose Emil |
Chief Medical Officer |
RSU 付与(制限付株式) |
215,000 |
$0.44 |
$94.6K |
215,000 |
| 2022-01-21 |
Wong Stephanie |
See Remarks |
RSU 源泉徴収 |
5,586 |
$0.49 |
$2.75K |
132,085 |
| 2022-01-21 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU 源泉徴収 |
4,794 |
$0.49 |
$2.36K |
172,434 |
| 2022-01-21 |
Parlati Francesco |
Sr. VP, Research |
RSU 源泉徴収 |
4,794 |
$0.49 |
$2.36K |
140,998 |
| 2022-01-21 |
Kuriakose Emil |
Chief Medical Officer |
RSU 源泉徴収 |
666 |
$0.49 |
$327.34 |
67,369 |
| 2022-01-04 |
Wong Stephanie |
See Remarks |
RSU 源泉徴収 |
18,077 |
$0.66 |
$11.94K |
137,671 |
| 2022-01-04 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU 源泉徴収 |
18,077 |
$0.66 |
$11.94K |
177,228 |
| 2022-01-04 |
Parlati Francesco |
Sr. VP, Research |
RSU 源泉徴収 |
18,077 |
$0.66 |
$11.94K |
145,792 |
| 2022-01-04 |
Kuriakose Emil |
Chief Medical Officer |
RSU 源泉徴収 |
3,855 |
$0.66 |
$2.55K |
68,035 |
| 2021-11-11 |
Orford Keith |
Director |
情報に基づく売り |
48,190 |
$0.88 |
$42.41K |
66,094 |
| 2021-11-10 |
Molineaux Susan |
President & CEO |
情報に基づく買い |
100,000 |
$0.85 |
$84.67K |
557,188 |
| 2021-11-10 |
Drachman Jonathan G |
Director |
情報に基づく買い |
200,000 |
$0.86 |
$171.9K |
200,000 |
| 2021-11-10 |
Molineaux Christopher |
Sr. VP, Development |
情報に基づく買い |
100,000 |
$0.85 |
$84.67K |
557,188 |
| 2021-11-10 |
Orford Keith |
Director |
情報に基づく売り |
30,000 |
$0.86 |
$25.7K |
114,284 |
| 2021-11-09 |
Orford Keith |
Director |
情報に基づく売り |
51,810 |
$0.84 |
$43.52K |
144,284 |
| 2021-11-08 |
Wong Stephanie |
See Remarks |
RSU 源泉徴収 |
15,566 |
$0.87 |
$13.54K |
155,748 |
| 2021-11-08 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU 源泉徴収 |
15,566 |
$0.87 |
$13.54K |
195,305 |
| 2021-11-08 |
Parlati Francesco |
Sr. VP, Research |
RSU 源泉徴収 |
15,566 |
$0.87 |
$13.54K |
163,869 |
| 2021-11-08 |
Kuriakose Emil |
Chief Medical Officer |
RSU 源泉徴収 |
3,077 |
$0.87 |
$2.68K |
69,390 |
| 2021-11-05 |
Wong Stephanie |
See Remarks |
RSU 付与(制限付株式) |
30,000 |
- |
- |
171,314 |
| 2021-11-05 |
Ray Sumita |
See Remarks |
RSU 付与(制限付株式) |
12,000 |
- |
- |
105,000 |
| 2021-11-05 |
Sjogren Eric |
Sr. VP, Drug Discovery |
RSU 付与(制限付株式) |
30,000 |
- |
- |
210,871 |
| 2021-11-05 |
Molineaux Christopher |
Sr. VP, Development |
RSU 付与(制限付株式) |
12,000 |
- |
- |
102,500 |
| 2021-11-05 |
Orford Keith |
Director |
RSU 付与(制限付株式) |
30,000 |
- |
- |
196,094 |
| 2021-11-05 |
Parlati Francesco |
Sr. VP, Research |
RSU 付与(制限付株式) |
30,000 |
- |
- |
179,435 |
| 2021-11-05 |
Kuriakose Emil |
Chief Medical Officer |
処分 |
33,375 |
$2.98 |
$99.46K |
- |
| 2021-11-05 |
Kuriakose Emil |
Chief Medical Officer |
RSU 付与(制限付株式) |
12,000 |
- |
- |
72,467 |
■ 情報付き — 公開市場取引(最も重要)
■ 情報なし(買い) — 報酬・オプション行使・転換
■ 情報なし(売り) — 源泉徴収・付与売却
■ 中立 — 贈与・信託・失効